End the Vaccine Carveout Act
- Bill Number
- S. 3853
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-02-11: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2026-03-02T17:17:00Z
AI-Generated Summary
Purpose of the Legislation
The "End the Vaccine Carveout Act" (S. 3853) aims to remove legal protections that currently shield vaccine manufacturers and administrators from lawsuits related to vaccine injuries or deaths. It seeks to allow individuals to directly sue these parties in court, rather than relying solely on a government-run compensation program, and specifically excludes COVID-19 vaccines from emergency liability immunities.
Key Provisions
- Amendments to the National Vaccine Injury Compensation Program (NVICP):
- Starting from the date of enactment, people injured or harmed by vaccines can file civil lawsuits (in state or federal courts) against vaccine manufacturers or administrators, regardless of whether they have filed a claim under the NVICP.
- If a person wins damages through a lawsuit or settlement, they cannot also seek compensation from the NVICP for the same injury, and any pending NVICP claim will be dismissed. The reverse is also true: NVICP compensation bars future lawsuits.
- Removes the requirement for a 6-month waiting period before electing to sue after filing an NVICP claim.
- Repeals and Adjustments to NVICP Rules:
- Eliminates sections of the law that require people to choose between the NVICP or a lawsuit (known as the "election" provision), set standards for manufacturer responsibility, and outline trial procedures in the U.S. Court of Federal Claims.
- Makes conforming changes to rules on attorneys' fees, compensation payments, and statutes of limitations (time limits for filing claims), ensuring lawsuits and NVICP claims are mutually exclusive without prior barriers.
- Exclusion of COVID-19 Vaccines:
- Amends the Public Readiness and Emergency Preparedness (PREP) Act to redefine "covered countermeasures" (products protected during public health emergencies). COVID-19 vaccines are explicitly excluded, removing their immunity from lawsuits during emergencies.
Significant Changes to Existing Law
- From NVICP (Public Health Service Act, Sections 2111–2134): Previously, the NVICP acted as a no-fault system where injured individuals had to first seek compensation through a special federal program before pursuing lawsuits, and manufacturers had limited liability. This bill dismantles that framework by allowing immediate access to civil courts, repealing the mandatory election process, and ending protections that barred most lawsuits against manufacturers.
- From PREP Act (Section 319F-3): Expands liability for COVID-19 vaccines by removing them from the list of protected emergency products, which currently shields manufacturers, distributors, and administrators from lawsuits during declared public health emergencies (like the COVID-19 pandemic).
- These changes effectively end the "liability shield" or "carveout" that has protected the vaccine industry since the 1980s, shifting from a compensation-focused system to one emphasizing personal lawsuits.
Potential Impacts
- On Government Agencies: The Department of Health and Human Services (HHS), which administers the NVICP, may see reduced workload and funding needs for the program, but could face increased oversight or legal challenges related to vaccine policy. Courts may experience a surge in vaccine-related cases.
- On Citizens: Individuals claiming vaccine injuries gain easier access to sue for damages (e.g., medical costs, pain, or lost wages), potentially leading to higher compensation but also longer legal battles. However, the mutual exclusivity with NVICP could limit options for some.
- On International Relations: Minimal direct impact, though it could affect U.S. vaccine manufacturers' global competitiveness if increased liability discourages production or exports of vaccines during future pandemics.
- Broader Effects: May influence vaccine availability or pricing, as manufacturers could pass on higher legal risks through costs, potentially slowing innovation or public vaccination rates.
Main Stakeholders Affected
- Vaccine Manufacturers and Administrators: Face direct exposure to lawsuits, increasing financial and legal risks (e.g., companies like Pfizer or healthcare providers giving shots).
- Individuals Injured by Vaccines: Benefit from new lawsuit options but lose the streamlined, no-fault NVICP as the primary path.
- Government and Taxpayers: HHS and the federal budget may save on NVICP payouts but could incur costs from defending policy changes or handling program wind-down.
- Legal System and Attorneys: Courts and lawyers specializing in personal injury may see more cases, with provisions adjusting fees for NVICP claims.
- Public Health Advocates: Groups promoting vaccination could be concerned about reduced manufacturer protections impacting emergency responses.
Notable Legal, Constitutional, or Political Implications
- Legal Implications: Shifts vaccine injury claims from an administrative compensation system (NVICP, a "no-fault" alternative to court) to traditional tort lawsuits, potentially overwhelming courts and increasing manufacturer defenses based on state laws. The mutual exclusivity rule prevents "double-dipping" but could raise questions about access to justice.
- Constitutional Implications: May invite challenges under the Fifth Amendment (due process or takings clause) if seen as altering established property interests for manufacturers, or under the Tenth Amendment if states argue it interferes with their tort laws. No explicit constitutional violations are targeted, but it promotes individual rights to sue over federal protections.
- Political Implications: As a bill introduced by Senators Rand Paul and Mike Lee (known for limited-government views), it reflects debates on corporate accountability versus public health incentives. It could polarize discussions on vaccine safety and government intervention, especially post-COVID, without altering core vaccine approval processes.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2026-02-11: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2026-02-11: Introduced in Senate
Bill Versions
- End the Vaccine Carveout Act — issued 2026-02-11 — PDF (7 pages)